Advertisement

High Sensitivity Measurement of Pancreatic Polypeptide and Its Variant in Serum and Plasma by LC-MS/MS

  • Hernando Escobar
  • Mark M. Kushnir
  • Alan L. RockwoodEmail author
  • A. Wayne Meikle
Part of the Methods in Molecular Biology book series (MIMB, volume 1378)

Abstract

Aliquots of serum or plasma samples are combined with stable isotope labeled internal standard. Pancreatic polypeptide (PP) and its truncated variant PP3-36 are enriched by incubation with anti-PP antibody conjugated to magnetic beads. Peptides are eluted from beads in acidic buffer and the samples analyzed using liquid chromatography coupled with tandem mass spectrometry. Instrumental analysis of PP and PP3-36 is performed using electrospray ionization ESI in positive ion mode and multiple reaction monitoring (MRM) acquisition.

Key words

Pancreatic polypeptide Peptide hormone Mass spectrometry Tandem mass spectrometry Clinic biomarker 

References

  1. 1.
    Tseng PH, Wu MS, Kao JH (2010) Recent advances in clinical application of gut hormones. J Formos Med Assoc 109:859–861CrossRefPubMedGoogle Scholar
  2. 2.
    Escobar H, Kushnir MM, Ray JA, Merrell MA, Gomez G, Fietkau R, Alan L, Rockwood AL, Meikle WA (2014) Measurement of pancreatic polypeptide and its peptide variant in human serum and plasma by immunocapture-liquid-chromatography-tandem mass spectrometry. Reference intervals and practical assay considerations. Biochem Physiol 3:140CrossRefGoogle Scholar
  3. 3.
    Pappas TN, Yovos JG, Ellison EC, O’Dorisio TM, Cataland WG, Pace WG, Carey LC (1981) Pancreatic polypeptide in acute pancreatitis and small-bowel infarction in dogs. Dig Dis Sci 26:1013–1018CrossRefPubMedGoogle Scholar
  4. 4.
    Adrian TE, Uttenthal LO, Williams SJ, Bloom SR (1986) Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. N Engl J Med 315:287–291CrossRefPubMedGoogle Scholar
  5. 5.
    Lamberts SW, Hofland LJ, Nobels FR (2001) Neuroendocrine tumor markers. Front Neuroendocrinol 22:309–339CrossRefPubMedGoogle Scholar
  6. 6.
    Ardill JES, O’Dorisio TM (2010) Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 40:777–790CrossRefGoogle Scholar
  7. 7.
    Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69:1310–1317PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Henriksen K, O’Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW (2013) Blood-based biomarker: the future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement 10:115–131PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Hernando Escobar
    • 1
  • Mark M. Kushnir
    • 1
  • Alan L. Rockwood
    • 1
    • 2
    Email author
  • A. Wayne Meikle
    • 1
    • 2
    • 3
  1. 1.ARUP Institute for Clinical and Experimental Pathology, ARUP LaboratoriesSalt Lake CityUSA
  2. 2.Department of PathologyUniversity of Utah School of MedicineSalt Lake CityUSA
  3. 3.Department of MedicineUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations